ClinicalTrials.gg
RecruitingNCT06804733Updated Dec 16, 2025

Efficacy of Individualized Aerobic Exercise Training in Patients With Inflammatory Bowel Disease

An interventional study of 12-week individualized aerobic exercise training and 12-week control intervention followed by 12-week aerobic exercise training in Inflammatory Bowel Disease (IBD), sponsored by Ningbo Medical Center Lihuili Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Ningbo Medical Center Lihuili Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 114 studies in Inflammatory Bowel Diseases with a site in China — 51 open to participants now, 55 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Planned enrollment
57th of 60
28 · median 97
Started
2025
with 25 others
No phase
28 of 114
16 open now
Primary completion
2027-05
later than 33 of 54 live
Registered
73rd of 114
by date

Among the 114 studies in Inflammatory Bowel Diseases with a site in China, this one is the 57th largest by planned enrollment of the 60 interventional ones that give a count, is one of 26 that started in 2025, is one of 28 with no phase, reaches primary completion later than 33 of the 54 other live ones, and was the 73rd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

51 of the 114 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a 12-week individualized aerobic training program helps manage inactive or mildly active inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) in adult patients aged 18-65 years. It will also assess participant compliance and the safety of the training program. The main questions it aims to answer are:

  1. Does this aerobic training program improve the cardiopulmonary function of participants?
  2. Does this aerobic training program help control disease activity?
  3. Does this aerobic training program improve participants' quality of life?

Researchers will divide participants into two groups. One group will participate in the training program directly. The other group will first undergo a 12-week control intervention (i.e., standard treatment) before proceeding to the training program.

Participants will:

  1. Take part in the individualized aerobic training program according to their baseline physical activity level for 12 weeks.
  2. Visit the clinic once every 4 weeks for check-ups and tests.
  3. Keep a diary of symptoms.
Read the detailed description

This study is a single-center, semi-crossover, randomized controlled trial. Patients will be consecutively screened from gastroenterology and inflammatory bowel disease clinics. After obtaining informed consent, they are randomly assigned in a 1:1 ratio, stratified by diagnosis (CD and UC). Group A immediately begins a 12-week individualized exercise training program, while Group B starts with a 12-week control intervention, consisting only of routine diagnosis and treatment, followed by the 12-week individualized exercise training. Comparisons are made for all patients before and after the exercise training and the control intervention.

Participants will be given different progressive individualized aerobic training schedules based on their baseline physical activity levels, with the exercise intensity increased every 4 weeks.

The implementation of the training program is based on telemedicine, utilizing a combination of methods including wearable devices, WeChat groups, and online form submissions to ensure quality control over the duration, intensity, and quality of the exercise training. Participants are required to wear fitness bands during the exercise training and use exercise software to record the exercise process, including duration, trajectory, maximal heart rate, and average heart rate. These data are promptly sent to the researchers upon completion of the exercise. Before the commencement of the exercise program, a dedicated researcher instructs the participants on how to use the bands to record the type of exercise, duration, and maximum heart rate, and then to timely fill in the exercise records on the online forms. Additionally, the researchers will discuss with the participants at the outset about the individualized exercise (including location, frequency, intensity, and type), the participants' motivation, expectations, and goals, as well as potential difficulties, aiming to enhance adherence to the training program.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with CD or UC for more than 3 months.
  • Disease activity in remission or mildly active (CD: CDAI \< 220; UC: pMS \< 5).
  • Baseline physical activity intensity is low, measured by the IPAQ Chinese version short form, and without a habit of "regular exercise".
  • Agree to participate in the study and accept a 12-week individualized aerobic exercise training program.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or planning to become pregnant within the next 3 months.
  • Presence of physical movement disorders or other chronic diseases that limit physical activity.
  • Having an ileostomy.
  • History of anal or intestinal surgery within the past 3 months.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Active comparator
    12-week control intervention followed by 12-week aerobic exercise training

    Behavioral: 12-week control intervention followed by 12-week aerobic exercise training

  • Experimental
    12-week aerobic exercise training directly

    Behavioral: 12-week individualized aerobic exercise training

Interventions

  • Behavioral12-week individualized aerobic exercise training

    After enrollment, subjects directly participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level measured by International Physical Activity Questionnaire (IPAQ), with the exercise intensity being increased every four weeks.

  • Behavioral12-week control intervention followed by 12-week aerobic exercise training

    After enrollment, subjects first undergo a 12-week control intervention (i.e., routine treatment) and then participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level IPAQ, with the exercise intensity being increased every four weeks.

06

What researchers measure

Primary outcomes

  1. Change in peak oxygen uptake (pVO2) (in ml/kg/min)

    Cardiorespiratory fitness measured by cardiopulmonary exercise testing (CPET)

    Time frame: At baseline and the end of intervention at week 12

Secondary outcomes

  1. Crohn's Disease Activity Index (CDAI)

    Measurement of patient-reported disease activity of CD participants. Higher scores mean higher activity. \<150 indicates remission, 150\~219 indicates mildly active.

    Time frame: At baseline, week 4, week 8 and the end of intervention at week 12

  2. Partial Mayo Score

    Measurement of Patient-reported disease activity of UC participants. Higher scores mean higher activity. 0\~1 indicates remission. 2\~4 indicates mildly active.

    Time frame: At baseline, week 4, week 8 and the end of intervention at week 12

  3. Concentration of fecal calprotectin

    Time frame: At baseline and the end of intervention at week 12

  4. Inflammatory Bowel Disease Questionnaire (IBDQ)

    32 questions grouped into four dimensions: bowel, systemic, social, and emotional. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL.

    Time frame: At baseline and the end of intervention at week 12

  5. Fatigue severity scale (FSS)

    Minimum value is 9 and maximum value is 63 with higher scores indicating higher level of fatigue.

    Time frame: At baseline and the end of intervention at week 12

  6. Hospital Anxiety and Depression Scale (HADS)

    Score of 0\~21 with higher scores indicates higher level of anxiety and depression

    Time frame: At baseline and the end of intervention at week 12

  7. International Physical Activity Questionnaire (IPAQ) short form

    A total IPAQ score is the sum of walking, moderate and vigorous metabolic equivalent of task (MET)-min/week.

    Time frame: At baseline and the end of intervention at week 12

  8. Body Mass Index (BMI) in kg/m^2

    Time frame: At baseline and the end of intervention at week 12

  9. Waist circumference in cm

    Time frame: At baseline and the end of intervention at week 12

  10. Concentration of serum fasting glucose in mmol/L

    Time frame: At baseline and the end of intervention at week 12

  11. Concentration of serum albumin in g/L

    Time frame: At baseline and the end of intervention at week 12

  12. Concentration of serum cholesterol in mmol/L

    Time frame: At baseline and the end of intervention at week 12

  13. Concentration of serum triglyceride in mmol/L

    Time frame: At baseline and the end of intervention at week 12

  14. Concentration of serum fasting lipoprotein in mmol/L

    Time frame: At baseline and the end of intervention at week 12

  15. Concentration of serum uric acid in mmol/L

    Time frame: At baseline and the end of intervention at week 12

  16. Oxygen uptake at aerobic threshold (in ml/kg/min)

    Oxygen uptake at aerobic threshold measured by CPET

    Time frame: at baseline and the end of intervention at week 12

  17. Peak oxygen uptake per heart rate (in ml/kg/min)

    Peak oxygen uptake per heart rate measured by CPET

    Time frame: at baseline and the end of intervention at week 12

  18. Maximal heart rate (in bpm)

    Maximal heart rate at peak measured by CPET

    Time frame: At baseline and the end of intervention at week 12

  19. Six-Minute Walk Test (in meters)

    Maximum walked distance in meters conducted according to guideline

    Time frame: At baseline and the end of intervention at week 12

  20. Exercise Benefits/Barriers Scale

    The Exercise Benefits/Barriers Scale (EBBS) will be used to assess participants' perceived benefits and barriers to exercise.

    Time frame: At baseline and the end of intervention at week 12

  21. Plasma C-reactive protein (mg/L)

    Time frame: At baseline and end of the intervention at week 12

  22. Plasma hemoglobin level (in g/L)

    Time frame: At baseline and end of the intervention at week 12

  23. Body fat percentage (%)

    Body fat percentage measured via body composition analysis

    Time frame: At baseline and end of the intervention at week 12

  24. Skeletal muscle mass (kg)

    Skeletal muscle mass (kg) measured via body composition analysis

    Time frame: At baseline and end of the intervention at week 12

07

Study locations

1 of 1 sites recruiting
  • the Affiliated Lihuili Hospital of Ningbo University
    Ningbo, Zhejiang 315040, China
    Recruiting
08

References and documents

Publications

  • Zhou Y, Liu H, Qian X, Zhang X, Xu F. Telemedicine-based individualised aerobic exercise training in Chinese adults with inactive or mildly active inflammatory bowel disease: study protocol for a single-centre, semi-crossover randomised controlled trial. BMJ Open. 2026 Jan 5;16(1):e103297. doi: 10.1136/bmjopen-2025-103297. PubMed 41490862 ↗

Individual participant data

Plan to share: Yes — All IPD collected throughout the trial will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Start Date: Upon publication of this clinical trial. End Date: Five years following publication.

Access criteria: Who can access the data? Researchers who provide a methodologically sound proposal. For what types of analysis? To achieve aims in the approved proposal. How can they access it? Proposals should be directed to drzhouying07@126.com. To gain access, data requestors will need to sign a data access agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 24 months is below that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2024
First posted
Feb 3, 2025
StartActual
May 1, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 31, 2027
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06804733
Lead sponsor
Ningbo Medical Center Lihuili Hospital
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
May 1, 2025
Primary completion
May 1, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Dec 16, 2025

Study contacts

Ying Zhou, M.D.
Contact
drzhouying07@126.com
8618395804423

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion